C54 Malignant neoplasm of corpus uteri

Name of the Condition

• Malignant neoplasm of corpus uteri (C54)
• Also known as uterine corpus cancer.

Summary

Malignant neoplasm of the corpus uteri is a type of cancer that originates in the body of the uterus, excluding the cervix. It is a subset of uterine cancer and primarily affects the endometrial lining or underlying muscular layer. This condition is often associated with hormonal imbalances and may present with abnormal bleeding or other pelvic symptoms.

Causes

The exact causes are not fully understood, but hormonal factors, particularly excess estrogen without progesterone, are strongly implicated. Genetic mutations, environmental exposures, and prior medical conditions may also contribute to its development.

Risk Factors

• Advanced age, especially postmenopausal women.
• Obesity, which increases estrogen levels.
• Hormone replacement therapy (estrogen-only).
• Family history of uterine, ovarian, or colorectal cancer.
• Conditions like polycystic ovary syndrome (PCOS) or endometrial hyperplasia.
• Prior radiation therapy to the pelvic region.

Symptoms

• Abnormal vaginal bleeding (e.g., postmenopausal bleeding or heavy menstrual periods).
• Pelvic pain or pressure.
• Unusual vaginal discharge, which may be watery or blood-tinged.
• Pain during intercourse.
• Unexplained weight loss or fatigue in advanced cases.

Diagnosis

Diagnosis involves a combination of clinical evaluation and diagnostic tests. A pelvic examination may reveal abnormalities, followed by imaging (e.g., transvaginal ultrasound) to assess uterine structure. A definitive diagnosis typically requires a biopsy of the uterine tissue, often obtained via hysteroscopy or dilation and curettage (D&C). Additional tests, such as MRI or CT scans, may be used to stage the cancer.

Treatment Options

Treatment depends on the stage and grade of the cancer. Common approaches include:

• Surgery (e.g., hysterectomy, with or without removal of ovaries/fallopian tubes).
• Radiation therapy to target residual cancer cells.
• Chemotherapy for advanced or recurrent disease.
• Hormone therapy (e.g., progestin therapy) for certain subtypes.

Prognosis and Follow-Up

Prognosis varies based on stage at diagnosis, with early-stage disease having a favorable outlook. Regular follow-up, including pelvic exams and imaging, is essential to monitor for recurrence. Long-term survival rates are generally high when detected early.

Complications

• Metastasis to nearby organs (e.g., ovaries, lymph nodes) or distant sites.
• Recurrence after treatment.
• Side effects from therapy (e.g., infertility, bowel/bladder dysfunction).
• Psychological impact due to diagnosis and treatment.

Lifestyle & Prevention

• Maintain a healthy weight to reduce estrogen-related risks.
• Manage hormonal imbalances (e.g., through progesterone therapy if needed).
• Avoid estrogen-only hormone replacement therapy without progesterone.
• Discuss family history with a healthcare provider to assess genetic risk.

When to Seek Professional Help

Seek prompt medical attention for abnormal vaginal bleeding, persistent pelvic pain, or unexplained discharge. Early evaluation is critical for timely diagnosis and treatment.

Tips for Medical Coders

• Code C54 is used for malignant neoplasms of the corpus uteri, excluding the cervix.
• Documentation should specify the anatomical site (e.g., endometrium, myometrium) if known, as this may influence coding specificity.
• Ensure differentiation from cervical or other uterine neoplasms to avoid miscoding.
• Follow ICD-10-CM guidelines for coding laterality (e.g., left vs. right) if applicable.